ストックスクリーナーアプリを入手
3.58
5.29%
0.18
アフターアワーズ：
3.56
-0.02
-0.56%
Can-Fite Biopharma Ltd ADR (CANF) 最新ニュース
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - Sahm
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewswire Inc.
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Why is Can-Fite BioPharma stock climbing today? - Investing.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
Wednesday's session: gap up and gap down stocks - ChartMill
Can Fite Biopharma stock surges 65% on pancreatic cancer data By Investing.com - Investing.com Nigeria
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
What's going on in today's pre-market session - ChartMill
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Top movers in Friday's pre-market session - ChartMill
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
CANF Stock Price, Quote & Chart - ChartMill
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Technical Analysis | Trend, Signals & Chart Patterns | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
CANFCan-Fite Biopharma Ltd ADR Stock Price and Quote - Finviz
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
Can Fite Biopharma stock rises on osteoarthritis study publication - Investing.com
D. Boral Capital upgrades Can-Fite BioPharma stock rating on oncology pipeline progress - Investing.com
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com Nigeria
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Curious about the most active stocks on Friday? - ChartMill
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Yahoo Finance
Can Fite Biopharma Ltd ADR (NYSE: CANF) Share Price, CANF Stock News, CANF Share Price & Updates - Kalkine
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Top movers in Monday's session - ChartMill
Jason Kolbert Analyst Performance at D. Boral Capital - MarketBeat
Stock Ratings | Morgan Stanley maintained its "neutral" rating on Palantir Technologies (PLTR) and raised its price target from $155 to $205. - Sahm
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Unusual volume stocks in Friday's session - ChartMill
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):